199 related articles for article (PubMed ID: 17385018)
1. Promise and progress for functional and molecular imaging of response to targeted therapies.
Stephen RM; Gillies RJ
Pharm Res; 2007 Jun; 24(6):1172-85. PubMed ID: 17385018
[TBL] [Abstract][Full Text] [Related]
2. Progress and Promise.
Zeitler EP; Di Biase L
Card Electrophysiol Clin; 2023 Sep; 15(3):xiii. PubMed ID: 37558309
[No Abstract] [Full Text] [Related]
3. More Than Just a Promise.
Treviño-Juarez AS
Acad Med; 2023 Jul; 98(7):762-763. PubMed ID: 36201487
[No Abstract] [Full Text] [Related]
4. The Role of VEGF Receptors as Molecular Target in Nuclear Medicine for Cancer Diagnosis and Combination Therapy.
Masłowska K; Halik PK; Tymecka D; Misicka A; Gniazdowska E
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802353
[TBL] [Abstract][Full Text] [Related]
5. Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses.
Ayat NR; Vaidya A; Yeung GA; Buford MN; Hall RC; Qiao PL; Yu X; Lu ZR
Front Oncol; 2019; 9():1351. PubMed ID: 31850230
[TBL] [Abstract][Full Text] [Related]
6. SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer.
Fernández-Pérez G; Sánchez-Escribano R; García-Vicente AM; Luna-Alcalá A; Ceballos-Viro J; Delgado-Bolton RC; Vilanova-Busquets JC; Sánchez-Rovira P; Fierro-Alanis MP; García-Figueiras R; Alés-Martínez JE
Clin Transl Oncol; 2018 Jul; 20(7):837-852. PubMed ID: 29256154
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Head and Neck Tumors with Functional MR Imaging.
Jansen JFA; Parra C; Lu Y; Shukla-Dave A
Magn Reson Imaging Clin N Am; 2016 Feb; 24(1):123-133. PubMed ID: 26613878
[TBL] [Abstract][Full Text] [Related]
8. The changing landscape of phase I trials in oncology.
Wong KM; Capasso A; Eckhardt SG
Nat Rev Clin Oncol; 2016 Feb; 13(2):106-17. PubMed ID: 26552953
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric monitoring of early response to antiangiogenic therapy: a sequential perfusion CT and PET/CT study in a rabbit VX2 tumor model.
Kim JI; Lee HJ; Kim YJ; Kim KG; Lee KW; Lee JH; Lee HJ; Lee WW
ScientificWorldJournal; 2014; 2014():701954. PubMed ID: 25383376
[TBL] [Abstract][Full Text] [Related]
10. Ultrasound-modulated fluorescence based on fluorescent microbubbles.
Liu Y; Feshitan JA; Wei MY; Borden MA; Yuan B
J Biomed Opt; 2014 Aug; 19(8):085005. PubMed ID: 25104407
[TBL] [Abstract][Full Text] [Related]
11. Tumour T1 changes in vivo are highly predictive of response to chemotherapy and reflect the number of viable tumour cells--a preclinical MR study in mice.
Weidensteiner C; Allegrini PR; Sticker-Jantscheff M; Romanet V; Ferretti S; McSheehy PM
BMC Cancer; 2014 Feb; 14():88. PubMed ID: 24528602
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CLT1-(Gd-DTPA) for Cancer MR Molecular Imaging in a Mouse Breast Cancer Model.
Ye F; Jeong EK; Parker D; Lu ZR
Bo Pu Xue Za Zhi; 2011; 2(5):325-330. PubMed ID: 24453461
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.
Cyran CC; Fu Y; Rogut V; Chaopathomkul B; Wendland MF; Shames DM; Brasch RC
Acad Radiol; 2013 Oct; 20(10):1256-63. PubMed ID: 24029057
[TBL] [Abstract][Full Text] [Related]
14. Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice.
Wang H; Liu B; Tian JH; Xu BX; Guan ZW; Qu BL; Liu CB; Wang RM; Chen YM; Zhang JM
World J Gastroenterol; 2010 Nov; 16(43):5416-23. PubMed ID: 21086558
[TBL] [Abstract][Full Text] [Related]
15. Protein-based MRI contrast agents for molecular imaging of prostate cancer.
Wei L; Li S; Yang J; Ye Y; Zou J; Wang L; Long R; Zurkiya O; Zhao T; Johnson J; Qiao J; Zhou W; Castiblanco A; Maor N; Chen Y; Mao H; Hu X; Yang JJ; Liu ZR
Mol Imaging Biol; 2011 Jun; 13(3):416-423. PubMed ID: 20574851
[TBL] [Abstract][Full Text] [Related]
16. The biology underlying molecular imaging in oncology: from genome to anatome and back again.
Gillies RJ; Anderson AR; Gatenby RA; Morse DL
Clin Radiol; 2010 Jul; 65(7):517-21. PubMed ID: 20541651
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
Harrison MR; Hahn NM; Pili R; Oh WK; Hammers H; Sweeney C; Kim K; Perlman S; Arnott J; Sidor C; Wilding G; Liu G
Invest New Drugs; 2011 Dec; 29(6):1465-74. PubMed ID: 20499131
[TBL] [Abstract][Full Text] [Related]
18. Molecular imaging and targeted therapies.
Morse DL; Gillies RJ
Biochem Pharmacol; 2010 Sep; 80(5):731-8. PubMed ID: 20399197
[TBL] [Abstract][Full Text] [Related]
19. Expanding the utility of beta-galactosidase complementation: piece by piece.
Broome AM; Bhavsar N; Ramamurthy G; Newton G; Basilion JP
Mol Pharm; 2010 Feb; 7(1):60-74. PubMed ID: 19899815
[TBL] [Abstract][Full Text] [Related]
20. Novel imaging modalities in gynecologic cancer.
Brooks RA; Powell MA
Curr Oncol Rep; 2009 Nov; 11(6):466-72. PubMed ID: 19840524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
